|
|
|
|
| LEADER |
00000cam a2200000Ii 4500 |
| 001 |
SCIDIR_on1280314757 |
| 003 |
OCoLC |
| 005 |
20231120010611.0 |
| 006 |
m o d |
| 007 |
cr cnu---unuuu |
| 008 |
211025s2021 mau o 000 0 eng d |
| 040 |
|
|
|a OPELS
|b eng
|e rda
|e pn
|c OPELS
|d OCLCF
|d OCLCO
|d SFB
|d OCLCQ
|d AAA
|d OCLCO
|
| 020 |
|
|
|z 9780128246054
|
| 020 |
|
|
|z 0128246057
|
| 035 |
|
|
|a (OCoLC)1280314757
|
| 050 |
|
4 |
|a QR360
|
| 082 |
0 |
4 |
|a 579.2
|2 23
|
| 245 |
0 |
0 |
|a Advances in virus research
|n Volume 111 /
|c edited by Thomas C. Mettenleiter, Margaret Kielian, Marilyn J. Roossinck.
|
| 264 |
|
1 |
|a Cambridge, MA :
|b Academic Press,
|c 2021.
|
| 300 |
|
|
|a 1 online resource (1 volume)
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 490 |
0 |
|
|a Advances in virus research ;
|v v. 111
|
| 588 |
0 |
|
|a Print version record.
|
| 505 |
0 |
|
|a Intro -- Advances in Virus Research -- Copyright -- Contents -- Contributors -- Chapter One: Parainfluenza virus entry at the onset of infection -- 1. Introduction to parainfluenza virus infection and entry -- 2. HN�s structure and receptor binding -- 3. F: Primed for action in its pre-fusion state -- 4. HN interaction with F and HN�s role in the activation of F -- 5. The transient intermediate state of F -- 6. Final stages of fusion and entry -- 7. Fitness requirements of the HN/F fusion complex in human lung -- 8. Inhibitors of entry -- 8.1. Antivirals targeting HN�s role in receptor binding -- 8.2. Hijacking HN to trigger F prematurely -- 8.3. Antibodies that target F�s conformation or HN-F interaction -- 8.4. Blocking fusion at F�s transitional intermediate state -- 9. Future directions -- Acknowledgments -- References -- Chapter Two: Molecular archeology of human viruses -- 1. Three decades of aDNA research and more than a century of virology set expectations for archeovirology -- 1.1. Lessons from aDNA and aRNA -- 1.2. Lessons from virology -- 2. Promises and pitfalls of archeovirology -- 2.1. Survival, detectability and authentication of ancient viral sequences -- 2.1.1. Specimen/sample types -- 2.1.2. Selection/detection method -- 2.1.3. Authentication/phylogenetic dating criterion -- 2.2. Key questions of archeovirology -- 2.2.1. Origins and timescales -- 2.2.2. Diversity and its temporal dynamics -- 3. Outlook -- References -- Chapter Three: Advancing phage therapy through the lens of virus host-breadth and emergence potential -- 1. Phage biology, and the history and promise of phage therapy -- 1.1. Combating antibiotic-resistant bacteria could capitalize on lytic phage biology -- 1.2. Historical development of phage therapy -- 1.2.1. Discovery of phages -- 1.2.2. Politics of phage therapy -- 1.2.3. Phage therapy vs antibiotics.
|
| 505 |
8 |
|
|a 1.3. Phage therapy offers many advantages over traditional antibiotics -- 1.4. Limitations to phage therapy -- 2. Phage host-range and development of generalized treatment -- 2.1. Host-range (specialism vs generalism) in lytic phages -- 2.2. Considerations for using few vs many phages in administered treatment -- 2.3. Observations and measures of host-range breadth in phages -- 2.4. Case example: Exploring host-range of lytic phages targeting P. aeruginosa -- 2.4.1. Study design to test killing ability of naturally-occurring phages across challenge hosts -- 2.4.2. Naturally-occurring phages differ in relative specialism vs generalism in host-use -- 2.4.3. Phage productivity on susceptible bacteria is additionally informative for gauging host-breadth -- 2.4.4. Using ``greedy algorithms�� to estimate useful combinations of phages for generalized treatment -- 2.4.5. Testing efficacy of a cocktail using in-vitro experiments on known and novel host strains -- 3. Phages can evolve in response to their environments, potentially altering host breadth -- 3.1. Evolution and ecology matter in phage-therapy development -- 3.1.1. Mutation rates affect phage evolution -- 3.1.2. Beyond mutations: Other sources of genetic material -- 3.1.3. Phages can evolve during treatment -- 3.1.4. Lessons from the emergence of zoonotic diseases -- 3.1.5. Lessons from experimental evolution -- 4. Conclusion -- Acknowledgments -- Appendix -- References -- Chapter Four: Alphavirus RNA replication in vertebrate cells -- 1. Introduction -- 2. Viral components of the RNA replication machinery -- 2.1. Precursors of ns-proteins -- 2.2. nsP1 -- 2.3. nsP2 -- 2.4. nsP3 -- 2.5. nsP4 -- 3. Host components of RNA replication machinery -- 4. Architecture, functioning, biogenesis and properties of replication complexes.
|
| 505 |
8 |
|
|a 5. Functional interactions between components of alphavirus RNA replication machinery -- 6. Replicase inhibitors -- 7. Conclusions and perspectives -- Acknowledgments -- References.
|
| 650 |
|
0 |
|a Virology.
|
| 650 |
|
0 |
|a Virology
|x Research.
|
| 650 |
|
6 |
|a Virologie.
|0 (CaQQLa)201-0008933
|
| 650 |
|
6 |
|a Virologie
|x Recherche.
|0 (CaQQLa)201-0032557
|
| 650 |
|
7 |
|a Virology
|2 fast
|0 (OCoLC)fst01167670
|
| 650 |
|
7 |
|a Virology
|x Research
|2 fast
|0 (OCoLC)fst01167675
|
| 700 |
1 |
|
|a Mettenleiter, Thomas C.,
|e editor.
|
| 700 |
1 |
|
|a Kielian, Margaret C.,
|d 1952-
|e editor.
|
| 700 |
1 |
|
|a Roossinck, Marilyn J.,
|e editor.
|
| 776 |
0 |
8 |
|i Print version:
|t Advances in virus research. Volume 111.
|d Amsterdam : Academic Press, 2021
|z 9780128246054
|w (OCoLC)1272893343
|
| 856 |
4 |
0 |
|u https://sciencedirect.uam.elogim.com/science/bookseries/00653527/111
|z Texto completo
|
